168 related articles for article (PubMed ID: 22475428)
1. Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms.
Baum RP; Kulkarni HR; Carreras C
Semin Nucl Med; 2012 May; 42(3):190-207. PubMed ID: 22475428
[TBL] [Abstract][Full Text] [Related]
2. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.
Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP
Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778
[TBL] [Abstract][Full Text] [Related]
3. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.
Bodei L; Mueller-Brand J; Baum RP; Pavel ME; Hörsch D; O'Dorisio MS; O'Dorisio TM; Howe JR; Cremonesi M; Kwekkeboom DJ; Zaknun JJ
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):800-16. PubMed ID: 23389427
[TBL] [Abstract][Full Text] [Related]
4. Peptide receptor radionuclide therapy with
Magalhães D; Sampaio IL; Ferreira G; Bogalho P; Martins-Branco D; Santos R; Duarte H
J Endocrinol Invest; 2019 Mar; 42(3):249-260. PubMed ID: 29949120
[TBL] [Abstract][Full Text] [Related]
5. NEN - the role of somatostatin receptor scintigraphy in clinical setting.
Opalińska M; Hubalewska-Dydejczyk A; Sowa-Staszczak A; Stefańska A
Nucl Med Rev Cent East Eur; 2016; 19(2):118-25. PubMed ID: 27479789
[TBL] [Abstract][Full Text] [Related]
6. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment.
Maecke HR; Reubi JC
J Nucl Med; 2011 Jun; 52(6):841-4. PubMed ID: 21571797
[TBL] [Abstract][Full Text] [Related]
8. Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology.
Salavati A; Prasad V; Schneider CP; Herbst R; Baum RP
Ann Nucl Med; 2012 May; 26(4):365-9. PubMed ID: 22361935
[TBL] [Abstract][Full Text] [Related]
9. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; de Herder WW; van Eijck CH; Kam BL; van Essen M; Teunissen JJ; Krenning EP
Semin Nucl Med; 2010 Mar; 40(2):78-88. PubMed ID: 20113677
[TBL] [Abstract][Full Text] [Related]
10. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
11. Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity?
Steffen IG; Mehl S; Heuck F; Elgeti F; Furth C; Amthauer H; Ruf J
Clin Nucl Med; 2009 Dec; 34(12):869-73. PubMed ID: 20139819
[TBL] [Abstract][Full Text] [Related]
12. [
Giovannini E; Giovacchini G; Borsò E; Lazzeri P; Riondato M; Leoncini R; Duce V; Ciarmiello A
Curr Radiopharm; 2019; 12(1):11-22. PubMed ID: 30539709
[TBL] [Abstract][Full Text] [Related]
13. Theranostics with Ga-68 somatostatin receptor PET/CT: monitoring response to peptide receptor radionuclide therapy.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):91-7. PubMed ID: 25029938
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical studies of peptide receptor radionuclide therapy.
Pool SE; Krenning EP; Koning GA; van Eijck CH; Teunissen JJ; Kam B; Valkema R; Kwekkeboom DJ; de Jong M
Semin Nucl Med; 2010 May; 40(3):209-18. PubMed ID: 20350630
[TBL] [Abstract][Full Text] [Related]
15. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
[TBL] [Abstract][Full Text] [Related]
16. Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors.
Basu S; Parghane RV; Kamaldeep ; Chakrabarty S
Semin Nucl Med; 2020 Sep; 50(5):447-464. PubMed ID: 32768008
[TBL] [Abstract][Full Text] [Related]
17. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.
Ruf J; Heuck F; Schiefer J; Denecke T; Elgeti F; Pascher A; Pavel M; Stelter L; Kropf S; Wiedenmann B; Amthauer H
Neuroendocrinology; 2010; 91(1):101-9. PubMed ID: 19996582
[TBL] [Abstract][Full Text] [Related]
18. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms.
Pasieka JL; McEwan AJ; Rorstad O
Surgery; 2004 Dec; 136(6):1218-26. PubMed ID: 15657579
[TBL] [Abstract][Full Text] [Related]
19. Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.
Schiesser M; Veit-Haibach P; Muller MK; Weber M; Bauerfeind P; Hany T; Clavien PA
Br J Surg; 2010 May; 97(5):691-7. PubMed ID: 20225244
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
